研究从欧洲和中东70个医学中心招募了2031名受试者,所有受试者均置入雅培依维莫司洗脱支架(Xience V)且对阿司匹林敏感,随机分配接受6个月(n=953)或24个月(n=941)的DAPT治疗,发现137名受试者对阿司匹林有抵抗性。
基于42个网页-相关网页
TWENTE试验随机1391例患者于佐它莫司(Resolute)与依维莫司(Xience)支架,用非劣势设计。靶血管失败的主要终点在两组相似(8.2对8.1%),支架血栓率低并相似。
基于28个网页-相关网页
Suzanne Baron教学在TCT现场宣布了EXCELQOL研究结果 研讨背景 借助有“行业金尺度”之称的依维莫司洗脱支架(XIENCE)优良临床表示,EXCEL研究获得了与NOBLE研究截然不同的结果。Gregg W.
基于12个网页-相关网页
XIENCE V 依维莫司洗脱支架 ; 雅培依维莫司 ; 依维莫司支架 ; 依维莫司药物洗脱支架
There was no difference between Xience and Taxus in terms of deaths or heart attack rates.
Xience和Taxus在心脏病发作致死方面的比率没有什么不同。
The analysts estimate that Xience could gain as much as 45 percent of a $1.8 billion American annual market for drug-coated stents over the next few years.
分析人士估计如果Xience能够顺利上市,它将在未来几年里获得药物涂层支架市场45%的份额,美国药物涂层支架市场每年的总量大概是18亿美元。
Medtronic is expected to gain approval for its drug-coated Endeavor stent as early as the end of December, and Wall Street anticipates that Xience could reach the market by the summer.
美敦力公司的药物涂层支架有望在12月底获得批准,华尔街预测Xience有望在明年夏天投放市场。
应用推荐